The cohort under analysis included stage IV NSCLC patients with available formalin-fixed, paraffin-embedded (FFPE) tumor tissue biosamples obtained before the treatment with PD-1-specific or PD-L1-specific ICI immunotherapeutic drugs, or both. The gene discussed is CD274; the disease is neoplasm.